Is the Neuropeptide PEN a Ligand of GPR83?


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Oct 2023
Historique:
received: 31 08 2023
revised: 03 10 2023
accepted: 05 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

G protein-coupled receptor 83 (GPR83) is a class A G protein-coupled receptor with predominant expression in the cerebellum and proposed function in the regulation of food intake and in anxiety-like behavior. The neuropeptide PEN has been suggested as a specific GPR83 ligand. However, conflicting reports exist about whether PEN is indeed able to bind and activate GPR83. This study was initiated to evaluate PEN as a potential ligand of GPR83. Employing several second messenger and other GPCR activation assays as well as a radioligand binding assay, and using multiple GPR83 plasmids and PEN peptides from different sources, no experimental evidence was found to support a role of PEN as a GPR83 ligand.

Identifiants

pubmed: 37894796
pii: ijms242015117
doi: 10.3390/ijms242015117
pmc: PMC10606834
pii:
doi:

Substances chimiques

Ligands 0
Receptors, G-Protein-Coupled 0
Neuropeptides 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Federal Ministry of Education and Research
ID : 03IPT614A
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1423-421152132
Organisme : Germany´s Excellence Strategy
ID : EXC2008-390540038-UniSysCat
Organisme : European Union
ID : 956314[ALLODD]

Références

PLoS One. 2011;6(12):e28152
pubmed: 22164236
J Immunol. 2006 Jul 1;177(1):209-15
pubmed: 16785516
Nature. 2020 Nov;587(7833):258-263
pubmed: 33116307
Mol Cell Biol. 2007 Dec;27(23):8065-72
pubmed: 17893329
J Biol Chem. 2006 Dec 15;281(50):38812-24
pubmed: 17015451
Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):64-9
pubmed: 18165312
Immunology. 2008 Nov;125(3):302-12
pubmed: 18479351
Nat Struct Mol Biol. 2015 May;22(5):362-9
pubmed: 25895059
Biochem J. 2011 Jan 1;433(1):11-8
pubmed: 21158738
Metabolism. 2012 Oct;61(10):1486-93
pubmed: 22560055
J Med Chem. 2016 Nov 23;59(22):10100-10112
pubmed: 27791374
Prog Mol Biol Transl Sci. 2018;159:1-25
pubmed: 30340784
F S Sci. 2020 Aug;1(1):67-77
pubmed: 35559741
ACS Chem Neurosci. 2019 Apr 17;10(4):1884-1891
pubmed: 30726666
Cell. 2019 Oct 31;179(4):895-908.e21
pubmed: 31675498
Gastroenterology. 1991 Aug;101(2):303-11
pubmed: 1712329
Front Neurosci. 2021 Aug 26;15:675769
pubmed: 34512237
Clin Transl Med. 2022 Nov;12(11):e1091
pubmed: 36314066
Nat Commun. 2013;4:1968
pubmed: 23744028
J Cell Sci. 2002 Feb 1;115(Pt 3):455-65
pubmed: 11861753
FEBS J. 2023 Jul;290(13):3461-3479
pubmed: 36853120
PLoS One. 2016 Dec 9;11(12):e0168260
pubmed: 27936173
SLAS Discov. 2020 Oct;25(9):1047-1063
pubmed: 32713278
Trends Pharmacol Sci. 2010 Mar;31(3):124-30
pubmed: 20060175
PLoS One. 2013;8(1):e53347
pubmed: 23335960
Sci Signal. 2016 Apr 26;9(425):ra43
pubmed: 27117253
Biochem Biophys Res Commun. 2007 Jan 12;352(2):397-403
pubmed: 17134677
Mol Pharmacol. 2022 May 23;:
pubmed: 35605991
World J Biol Chem. 2018 Dec 12;9(3):25-35
pubmed: 30595812
J Endocr Soc. 2018 Dec 06;3(2):314-323
pubmed: 30652132

Auteurs

Yvonne Giesecke (Y)

Tumor Targeting Group, Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.

Vahid Asimi (V)

Tumor Targeting Group, Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.

Valentina Stulberg (V)

Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.

Gunnar Kleinau (G)

Group Structural Biology of Cellular Signaling, Institute of Medical Physics and Biophysics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.

Patrick Scheerer (P)

Group Structural Biology of Cellular Signaling, Institute of Medical Physics and Biophysics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.

Beate Koksch (B)

Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.

Carsten Grötzinger (C)

Tumor Targeting Group, Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin, Germany.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH